LOCUS       IF2P_HUMAN              1220 aa            linear   PRI 29-MAY-2024
DEFINITION  RecName: Full=Eukaryotic translation initiation factor 5B;
            Short=eIF-5B; AltName: Full=Translation initiation factor IF-2.
ACCESSION   O60841
VERSION     O60841.4
DBSOURCE    UniProtKB: locus IF2P_HUMAN, accession O60841;
            class: standard.
            extra accessions:O95805,Q53RV7,Q53SI8,Q9UF81,Q9UMN7
            created: Dec 15, 1998.
            sequence updated: Nov 24, 2009.
            annotation updated: May 29, 2024.
            xrefs: AJ006776.1, CAB44357.1, AF078035.1, AAD16006.1, AC018690.5,
            AAY24313.1, AC079447.4, AAX93258.1, AB018284.1, BAA34461.2,
            AL133563.1, CAB63717.1, AJ006412.1, CAA07018.1, T43483,
            NP_056988.3, 7TQL_1
            xrefs (non-sequence databases): CCDS:CCDS42721.1, PDBsum:7TQL,
            AlphaFoldDB:O60841, EMDB:EMD-26067, SMR:O60841, BioGRID:115024,
            IntAct:O60841, MINT:O60841, STRING:9606.ENSP00000289371,
            ChEMBL:CHEMBL4105852, GlyGen:O60841, iPTMnet:O60841,
            MetOSite:O60841, PhosphoSitePlus:O60841, SwissPalm:O60841,
            BioMuta:EIF5B, EPD:O60841, jPOST:O60841, MassIVE:O60841,
            MaxQB:O60841, PaxDb:9606-ENSP00000289371, PeptideAtlas:O60841,
            ProteomicsDB:49628, Pumba:O60841, Antibodypedia:32818, DNASU:9669,
            Ensembl:ENST00000289371.11, Ensembl:ENSP00000289371.5,
            Ensembl:ENSG00000158417.12, GeneID:9669, KEGG:hsa:9669,
            MANE-Select:ENST00000289371.11, UCSC:uc002tab.4, AGR:HGNC:30793,
            CTD:9669, DisGeNET:9669, GeneCards:EIF5B, HGNC:30793,
            HPA:ENSG00000158417, MIM:606086, neXtProt:NX_O60841,
            OpenTargets:ENSG00000158417, PharmGKB:PA134864457,
            VEuPathDB:HostDB:ENSG00000158417, eggNOG:KOG1144,
            GeneTree:ENSGT00940000162583, HOGENOM:CLU_002656_0_1_1,
            InParanoid:O60841, OMA:EFAVMLC, OrthoDB:169393at2759,
            PhylomeDB:O60841, TreeFam:TF101535, BRENDA:3.6.5.3,
            PathwayCommons:O60841, Reactome:R-HSA-72706, SignaLink:O60841,
            SIGNOR:O60841, BioGRID-ORCS:9669, ChiTaRS:EIF5B, GeneWiki:EIF5B,
            GenomeRNAi:9669, Pharos:O60841, PRO:PR:O60841,
            Proteomes:UP000005640, RNAct:O60841, Bgee:ENSG00000158417,
            ExpressionAtlas:O60841, GO:0005737, GO:0005829, GO:0005739,
            GO:0045202, GO:0005525, GO:0003924, GO:0046872, GO:0003723,
            GO:0003743, GO:0000049, GO:0006446, GO:0042255, GO:0006413,
            CDD:cd03703, CDD:cd16266, CDD:cd01887, Gene3D:3.40.50.300,
            Gene3D:2.40.30.10, Gene3D:3.40.50.10050, InterPro:IPR029459,
            InterPro:IPR027417, InterPro:IPR005225, InterPro:IPR000795,
            InterPro:IPR015760, InterPro:IPR023115, InterPro:IPR036925,
            InterPro:IPR009000, NCBIfam:TIGR00231, PANTHER:PTHR43381:SF4,
            PANTHER:PTHR43381, Pfam:PF00009, Pfam:PF14578, Pfam:PF11987,
            PRINTS:PR00315, SUPFAM:SSF52156, SUPFAM:SSF52540, SUPFAM:SSF50447,
            PROSITE:PS51722
KEYWORDS    3D-structure; Cytoplasm; Direct protein sequencing; GTP-binding;
            Hydrolase; Initiation factor; Metal-binding; Nucleotide-binding;
            Phosphoprotein; Protein biosynthesis; Reference proteome.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
            Catarrhini; Hominidae; Homo.
REFERENCE   1  (residues 1 to 1220)
  AUTHORS   Wilson,S.A., Sieiro-Vazquez,C., Edwards,N.J., Iourin,O.,
            Byles,E.D., Kotsopoulou,E., Adamson,C.S., Kingsman,S.M.,
            Kingsman,A.J. and Martin-Rendon,E.
  TITLE     Cloning and characterization of hIF2, a human homologue of
            bacterial translation initiation factor 2, and its interaction with
            HIV-1 matrix
  JOURNAL   Biochem J 342 (Pt 1) (Pt 1), 97-103 (1999)
   PUBMED   10432305
  REMARK    NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT THR-522.;
            TISSUE=Cervix carcinoma
REFERENCE   2  (residues 1 to 1220)
  AUTHORS   Lee,J.H., Choi,S.K., Roll-Mecak,A., Burley,S.K. and Dever,T.E.
  TITLE     Universal conservation in translation initiation revealed by human
            and archaeal homologs of bacterial translation initiation factor
            IF2
  JOURNAL   Proc Natl Acad Sci U S A 96 (8), 4342-4347 (1999)
   PUBMED   10200264
  REMARK    NUCLEOTIDE SEQUENCE [MRNA], MUTAGENESIS OF VAL-640; HIS-706 AND
            ASP-759, CHARACTERIZATION, AND VARIANT THR-522.;
            TISSUE=Testis
REFERENCE   3  (residues 1 to 1220)
  AUTHORS   Nagase,T., Ishikawa,K., Suyama,M., Kikuno,R., Miyajima,N.,
            Tanaka,A., Kotani,H., Nomura,N. and Ohara,O.
  TITLE     Prediction of the coding sequences of unidentified human genes. XI.
            The complete sequences of 100 new cDNA clones from brain which code
            for large proteins in vitro
  JOURNAL   DNA Res 5 (5), 277-286 (1998)
   PUBMED   9872452
  REMARK    NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].;
            TISSUE=Brain
REFERENCE   4  (residues 1 to 1220)
  AUTHORS   Hillier,L.W., Graves,T.A., Fulton,R.S., Fulton,L.A., Pepin,K.H.,
            Minx,P., Wagner-McPherson,C., Layman,D., Wylie,K., Sekhon,M.,
            Becker,M.C., Fewell,G.A., Delehaunty,K.D., Miner,T.L., Nash,W.E.,
            Kremitzki,C., Oddy,L., Du,H., Sun,H., Bradshaw-Cordum,H., Ali,J.,
            Carter,J., Cordes,M., Harris,A., Isak,A., van Brunt,A., Nguyen,C.,
            Du,F., Courtney,L., Kalicki,J., Ozersky,P., Abbott,S.,
            Armstrong,J., Belter,E.A., Caruso,L., Cedroni,M., Cotton,M.,
            Davidson,T., Desai,A., Elliott,G., Erb,T., Fronick,C., Gaige,T.,
            Haakenson,W., Haglund,K., Holmes,A., Harkins,R., Kim,K.,
            Kruchowski,S.S., Strong,C.M., Grewal,N., Goyea,E., Hou,S., Levy,A.,
            Martinka,S., Mead,K., McLellan,M.D., Meyer,R., Randall-Maher,J.,
            Tomlinson,C., Dauphin-Kohlberg,S., Kozlowicz-Reilly,A., Shah,N.,
            Swearengen-Shahid,S., Snider,J., Strong,J.T., Thompson,J.,
            Yoakum,M., Leonard,S., Pearman,C., Trani,L., Radionenko,M.,
            Waligorski,J.E., Wang,C., Rock,S.M., Tin-Wollam,A.M., Maupin,R.,
            Latreille,P., Wendl,M.C., Yang,S.P., Pohl,C., Wallis,J.W.,
            Spieth,J., Bieri,T.A., Berkowicz,N., Nelson,J.O., Osborne,J.,
            Ding,L., Meyer,R., Sabo,A., Shotland,Y., Sinha,P., Wohldmann,P.E.,
            Cook,L.L., Hickenbotham,M.T., Eldred,J., Williams,D., Jones,T.A.,
            She,X., Ciccarelli,F.D., Izaurralde,E., Taylor,J., Schmutz,J.,
            Myers,R.M., Cox,D.R., Huang,X., McPherson,J.D., Mardis,E.R.,
            Clifton,S.W., Warren,W.C., Chinwalla,A.T., Eddy,S.R., Marra,M.A.,
            Ovcharenko,I., Furey,T.S., Miller,W., Eichler,E.E., Bork,P.,
            Suyama,M., Torrents,D., Waterston,R.H. and Wilson,R.K.
  TITLE     Generation and annotation of the DNA sequences of human chromosomes
            2 and 4
  JOURNAL   Nature 434 (7034), 724-731 (2005)
   PUBMED   15815621
  REMARK    NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
REFERENCE   5  (residues 1 to 1220)
  AUTHORS   Bienvenut,W.V., Waridel,P. and Quadroni,M.
  TITLE     Direct Submission
  JOURNAL   Submitted (??-MAR-2009) to UniProtKB
  REMARK    PROTEIN SEQUENCE OF 9-33; 77-94; 106-122; 180-197; 206-224;
            285-298; 425-436; 629-644; 653-683; 695-713; 749-757; 766-777;
            882-902; 1000-1015; 1044-1055; 1096-1120 AND 1175-1185,
            PHOSPHORYLATION AT SER-190, AND IDENTIFICATION BY MASS
            SPECTROMETRY.;
            TISSUE=Cervix carcinoma
REFERENCE   6  (residues 1 to 1220)
  AUTHORS   Bechtel,S., Rosenfelder,H., Duda,A., Schmidt,C.P., Ernst,U.,
            Wellenreuther,R., Mehrle,A., Schuster,C., Bahr,A., Blocker,H.,
            Heubner,D., Hoerlein,A., Michel,G., Wedler,H., Kohrer,K.,
            Ottenwalder,B., Poustka,A., Wiemann,S. and Schupp,I.
  TITLE     The full-ORF clone resource of the German cDNA Consortium
  JOURNAL   BMC Genomics 8, 399 (2007)
   PUBMED   17974005
  REMARK    NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 89-1220.;
            TISSUE=Testis
            Publication Status: Online-Only
REFERENCE   7  (residues 1 to 1220)
  AUTHORS   Stanchi,F., Bertocco,E., Toppo,S., Dioguardi,R., Simionati,B.,
            Cannata,N., Zimbello,R., Lanfranchi,G. and Valle,G.
  TITLE     Characterization of 16 novel human genes showing high similarity to
            yeast sequences
  JOURNAL   Yeast 18 (1), 69-80 (2001)
   PUBMED   11124703
  REMARK    NUCLEOTIDE SEQUENCE [MRNA] OF 833-1220.
REFERENCE   8  (residues 1 to 1220)
  AUTHORS   Pestova,T.V., Lomakin,I.B., Lee,J.H., Choi,S.K., Dever,T.E. and
            Hellen,C.U.
  TITLE     The joining of ribosomal subunits in eukaryotes requires eIF5B
  JOURNAL   Nature 403 (6767), 332-335 (2000)
   PUBMED   10659855
  REMARK    FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
REFERENCE   9  (residues 1 to 1220)
  AUTHORS   Marintchev,A., Kolupaeva,V.G., Pestova,T.V. and Wagner,G.
  TITLE     Mapping the binding interface between human eukaryotic initiation
            factors 1A and 5B: a new interaction between old partners
  JOURNAL   Proc Natl Acad Sci U S A 100 (4), 1535-1540 (2003)
   PUBMED   12569173
  REMARK    INTERACTION WITH EIF1AX.
REFERENCE   10 (residues 1 to 1220)
  AUTHORS   Olsen,J.V., Blagoev,B., Gnad,F., Macek,B., Kumar,C., Mortensen,P.
            and Mann,M.
  TITLE     Global, in vivo, and site-specific phosphorylation dynamics in
            signaling networks
  JOURNAL   Cell 127 (3), 635-648 (2006)
   PUBMED   17081983
  REMARK    PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-107; SER-113; SER-164
            AND SER-214, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
            ANALYSIS].;
            TISSUE=Cervix carcinoma
REFERENCE   11 (residues 1 to 1220)
  AUTHORS   Giorgianni,F., Zhao,Y., Desiderio,D.M. and Beranova-Giorgianni,S.
  TITLE     Toward a global characterization of the phosphoproteome in prostate
            cancer cells: identification of phosphoproteins in the LNCaP cell
            line
  JOURNAL   Electrophoresis 28 (12), 2027-2034 (2007)
   PUBMED   17487921
  REMARK    PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-214, AND
            IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].;
            TISSUE=Prostate cancer
REFERENCE   12 (residues 1 to 1220)
  AUTHORS   Yu,L.R., Zhu,Z., Chan,K.C., Issaq,H.J., Dimitrov,D.S. and
            Veenstra,T.D.
  TITLE     Improved titanium dioxide enrichment of phosphopeptides from HeLa
            cells and high confident phosphopeptide identification by
            cross-validation of MS/MS and MS/MS/MS spectra
  JOURNAL   J Proteome Res 6 (11), 4150-4162 (2007)
   PUBMED   17924679
  REMARK    PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-214, AND
            IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].;
            TISSUE=Cervix carcinoma
REFERENCE   13 (residues 1 to 1220)
  AUTHORS   Carrascal,M., Ovelleiro,D., Casas,V., Gay,M. and Abian,J.
  TITLE     Phosphorylation analysis of primary human T lymphocytes using
            sequential IMAC and titanium oxide enrichment
  JOURNAL   J Proteome Res 7 (12), 5167-5176 (2008)
   PUBMED   19367720
  REMARK    PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-214, AND
            IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].;
            TISSUE=T-cell
REFERENCE   14 (residues 1 to 1220)
  AUTHORS   Zahedi,R.P., Lewandrowski,U., Wiesner,J., Wortelkamp,S.,
            Moebius,J., Schutz,C., Walter,U., Gambaryan,S. and Sickmann,A.
  TITLE     Phosphoproteome of resting human platelets
  JOURNAL   J Proteome Res 7 (2), 526-534 (2008)
   PUBMED   18088087
  REMARK    IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].;
            TISSUE=Platelet
REFERENCE   15 (residues 1 to 1220)
  AUTHORS   Dephoure,N., Zhou,C., Villen,J., Beausoleil,S.A., Bakalarski,C.E.,
            Elledge,S.J. and Gygi,S.P.
  TITLE     A quantitative atlas of mitotic phosphorylation
  JOURNAL   Proc Natl Acad Sci U S A 105 (31), 10762-10767 (2008)
   PUBMED   18669648
  REMARK    PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-107; SER-113;
            TYR-134; SER-135; SER-137; SER-164; SER-182; SER-183; SER-186;
            SER-190; THR-301; SER-547; SER-560; SER-588 AND SER-595, AND
            IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].;
            TISSUE=Cervix carcinoma
REFERENCE   16 (residues 1 to 1220)
  AUTHORS   Han,G., Ye,M., Zhou,H., Jiang,X., Feng,S., Jiang,X., Tian,R.,
            Wan,D., Zou,H. and Gu,J.
  TITLE     Large-scale phosphoproteome analysis of human liver tissue by
            enrichment and fractionation of phosphopeptides with strong anion
            exchange chromatography
  JOURNAL   Proteomics 8 (7), 1346-1361 (2008)
   PUBMED   18318008
  REMARK    PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-107; SER-113 AND
            SER-164, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
            ANALYSIS].;
            TISSUE=Liver
REFERENCE   17 (residues 1 to 1220)
  AUTHORS   de Breyne,S., Bonderoff,J.M., Chumakov,K.M., Lloyd,R.E. and
            Hellen,C.U.
  TITLE     Cleavage of eukaryotic initiation factor eIF5B by enterovirus 3C
            proteases
  JOURNAL   Virology 378 (1), 118-122 (2008)
   PUBMED   18572216
  REMARK    PROTEOLYTIC CLEAVAGE (MICROBIAL INFECTION).
REFERENCE   18 (residues 1 to 1220)
  AUTHORS   Gauci,S., Helbig,A.O., Slijper,M., Krijgsveld,J., Heck,A.J. and
            Mohammed,S.
  TITLE     Lys-N and trypsin cover complementary parts of the phosphoproteome
            in a refined SCX-based approach
  JOURNAL   Anal Chem 81 (11), 4493-4501 (2009)
   PUBMED   19413330
  REMARK    IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
REFERENCE   19 (residues 1 to 1220)
  AUTHORS   Mayya,V., Lundgren,D.H., Hwang,S.I., Rezaul,K., Wu,L., Eng,J.K.,
            Rodionov,V. and Han,D.K.
  TITLE     Quantitative phosphoproteomic analysis of T cell receptor signaling
            reveals system-wide modulation of protein-protein interactions
  JOURNAL   Sci Signal 2 (84), ra46 (2009)
   PUBMED   19690332
  REMARK    PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-113; TYR-134;
            SER-135; SER-137; SER-164; SER-182; SER-183; SER-186 AND SER-214,
            AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].;
            TISSUE=Leukemic T-cell
            Publication Status: Online-Only
REFERENCE   20 (residues 1 to 1220)
  AUTHORS   Olsen,J.V., Vermeulen,M., Santamaria,A., Kumar,C., Miller,M.L.,
            Jensen,L.J., Gnad,F., Cox,J., Jensen,T.S., Nigg,E.A., Brunak,S. and
            Mann,M.
  TITLE     Quantitative phosphoproteomics reveals widespread full
            phosphorylation site occupancy during mitosis
  JOURNAL   Sci Signal 3 (104), ra3 (2010)
   PUBMED   20068231
  REMARK    PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-113; SER-135;
            SER-137; SER-164; SER-182; SER-186; SER-190; SER-214; THR-301;
            SER-588; SER-589; SER-591 AND SER-595, AND IDENTIFICATION BY MASS
            SPECTROMETRY [LARGE SCALE ANALYSIS].;
            TISSUE=Cervix carcinoma
            Publication Status: Online-Only
REFERENCE   21 (residues 1 to 1220)
  AUTHORS   Rigbolt,K.T., Prokhorova,T.A., Akimov,V., Henningsen,J.,
            Johansen,P.T., Kratchmarova,I., Kassem,M., Mann,M., Olsen,J.V. and
            Blagoev,B.
  TITLE     System-wide temporal characterization of the proteome and
            phosphoproteome of human embryonic stem cell differentiation
  JOURNAL   Sci Signal 4 (164), rs3 (2011)
   PUBMED   21406692
  REMARK    PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-107; SER-113;
            TYR-134; SER-135; SER-137; SER-164; SER-171; SER-214 AND THR-498,
            AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
            Publication Status: Online-Only
REFERENCE   22 (residues 1 to 1220)
  AUTHORS   Zhou,H., Di Palma,S., Preisinger,C., Peng,M., Polat,A.N., Heck,A.J.
            and Mohammed,S.
  TITLE     Toward a comprehensive characterization of a human cancer cell
            phosphoproteome
  JOURNAL   J Proteome Res 12 (1), 260-271 (2013)
   PUBMED   23186163
  REMARK    PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-66; SER-107; SER-113;
            SER-135; SER-137; SER-164; SER-186; SER-214; SER-222; SER-438 AND
            SER-1168, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
            ANALYSIS].;
            TISSUE=Cervix carcinoma, and Erythroleukemia
REFERENCE   23 (residues 1 to 1220)
  AUTHORS   Bian,Y., Song,C., Cheng,K., Dong,M., Wang,F., Huang,J., Sun,D.,
            Wang,L., Ye,M. and Zou,H.
  TITLE     An enzyme assisted RP-RPLC approach for in-depth analysis of human
            liver phosphoproteome
  JOURNAL   J Proteomics 96, 253-262 (2014)
   PUBMED   24275569
  REMARK    PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-107; SER-113;
            SER-135; SER-137; SER-164; SER-182; SER-190 AND SER-214, AND
            IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].;
            TISSUE=Liver
REFERENCE   24 (residues 1 to 1220)
  AUTHORS   Lin,K.Y., Nag,N., Pestova,T.V. and Marintchev,A.
  TITLE     Human eIF5 and eIF1A Compete for Binding to eIF5B
  JOURNAL   Biochemistry 57 (40), 5910-5920 (2018)
   PUBMED   30211544
  REMARK    INTERACTION WITH EIF5 AND EIF1AX.
REFERENCE   25 (residues 1 to 1220)
  AUTHORS   Lapointe,C.P., Grosely,R., Sokabe,M., Alvarado,C., Wang,J.,
            Montabana,E., Villa,N., Shin,B.S., Dever,T.E., Fraser,C.S.,
            Fernandez,I.S. and Puglisi,J.D.
  TITLE     eIF5B and eIF1A reorient initiator tRNA to allow ribosomal subunit
            joining
  JOURNAL   Nature 607 (7917), 185-190 (2022)
   PUBMED   35732735
  REMARK    STRUCTURE BY ELECTRON MICROSCOPY (3.40 ANGSTROMS) OF 602-1219 IN
            COMPLEX WITH A GTP ANALOG, FUNCTION, CATALYTIC ACTIVITY, PROBABLE
            ACTIVE SITE, MUTAGENESIS OF HIS-706; ARG-1105; ARG-1174;
            1188-ARG-GLN-1189; ARG-1199 AND 1218-GLU-ILE-1219, AND INTERACTION
            WITH EIF1AX.
REFERENCE   26 (residues 1 to 1220)
  AUTHORS   Burkard,T.R., Planyavsky,M., Kaupe,I., Breitwieser,F.P.,
            Burckstummer,T., Bennett,K.L., Superti-Furga,G. and Colinge,J.
  TITLE     Initial characterization of the human central proteome
  JOURNAL   BMC Syst Biol 5, 17 (2011)
   PUBMED   21269460
  REMARK    VARIANT [LARGE SCALE ANALYSIS] THR-522, AND IDENTIFICATION BY MASS
            SPECTROMETRY [LARGE SCALE ANALYSIS].
            Publication Status: Online-Only
COMMENT     On or before Nov 24, 2009 this sequence version replaced
            gi:74726610, gi:74740714, O60841.3.
            [FUNCTION] Plays a role in translation initiation (PubMed:10659855,
            PubMed:35732735). Ribosome-dependent GTPase that promotes the
            joining of the 60S ribosomal subunit to the pre-initiation complex
            to form the 80S initiation complex with the initiator
            methionine-tRNA in the P-site base paired to the start codon
            (PubMed:10659855, PubMed:35732735). Together with eIF1A (EIF1AX),
            actively orients the initiator methionine-tRNA in a conformation
            that allows 60S ribosomal subunit joining to form the 80S
            initiation complex (PubMed:12569173, PubMed:35732735). Is released
            after formation of the 80S initiation complex (PubMed:35732735).
            Its GTPase activity is not essential for ribosomal subunits
            joining, but GTP hydrolysis is needed for eIF1A (EIF1AX) ejection
            quickly followed by EIF5B release to form elongation-competent
            ribosomes (PubMed:10659855, PubMed:35732735). In contrast to its
            procaryotic homolog, does not promote recruitment of Met-rRNA to
            the small ribosomal subunit (PubMed:10659855).
            {ECO:0000269|PubMed:10659855, ECO:0000269|PubMed:12569173,
            ECO:0000269|PubMed:35732735}.
            [CATALYTIC ACTIVITY] Reaction=GTP + H2O = GDP + H(+) + phosphate;
            Xref=Rhea:RHEA:19669, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
            ChEBI:CHEBI:37565, ChEBI:CHEBI:43474, ChEBI:CHEBI:58189;
            EC=3.6.5.3; Evidence={ECO:0000269|PubMed:10659855,
            ECO:0000305|PubMed:35732735}; PhysiologicalDirection=left-to-right;
            Xref=Rhea:RHEA:19670; Evidence={ECO:0000269|PubMed:10659855,
            ECO:0000305|PubMed:35732735}.
            [COFACTOR] Name=a monovalent cation; Xref=ChEBI:CHEBI:60242;
            Evidence={ECO:0000250|UniProtKB:G0S8G9}; Note=Binds 1 monovalent
            cation per monomer in the active site. Structural cofactor that
            stabilizes the GTP-bound 'on' state. May also act as a transition
            state stabilizer of the hydrolysis reaction.
            {ECO:0000250|UniProtKB:G0S8G9}.
            [BIOPHYSICOCHEMICAL PROPERTIES] Kinetic parameters: Vmax=1
            pmol/min/ug enzyme {ECO:0000269|PubMed:10659855}; Note=Obtained in
            the presence of 40S and 60S ribosomal subunits. 60S ribosomal
            subunit is necessary for enzyme activation, while 40S ribosomal
            subunit is not.
            [SUBUNIT] Interacts through its C-terminal domain (CTD) with the
            CTD of eIF1A (EIF1AX) or with the CTD of EIF5 (mutually exclusive)
            through a common binding site (PubMed:30211544). Interacts with
            eIF1A (EIF1AX) from the location of the start codon by the 43S
            complex until the formation of the 80S complex (PubMed:12569173,
            PubMed:35732735). Interacts with ANXA5 in a calcium and
            phospholipid-dependent manner (By similarity).
            {ECO:0000250|UniProtKB:B2GUV7, ECO:0000269|PubMed:35732735}.
            [INTERACTION] O60841; O14602: EIF1AY; NbExp=2; IntAct=EBI-928530,
            EBI-286439; O60841; P14921: ETS1; NbExp=2; IntAct=EBI-928530,
            EBI-913209; O60841; P28799: GRN; NbExp=3; IntAct=EBI-928530,
            EBI-747754; O60841; O43933: PEX1; NbExp=3; IntAct=EBI-928530,
            EBI-988601; O60841; O76024: WFS1; NbExp=3; IntAct=EBI-928530,
            EBI-720609.
            [SUBCELLULAR LOCATION] Cytoplasm {ECO:0000250|UniProtKB:Q05D44}.
            [PTM] (Microbial infection) Cleaved and inactivated by the protease
            3C of poliovirus, Coxsackievirus B3 and Human rhinovirus 14,
            allowing the virus to shutoff the host cell translation.
            {ECO:0000269|PubMed:18572216}.
            [SIMILARITY] Belongs to the TRAFAC class translation factor GTPase
            superfamily. Classic translation factor GTPase family. IF-2
            subfamily. {ECO:0000305}.
            [SEQUENCE CAUTION] Sequence=BAA34461.2; Type=Erroneous initiation;
            Note=Truncated N-terminus.; Evidence={ECO:0000305}.
FEATURES             Location/Qualifiers
     source          1..1220
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
     gene            1..1220
                     /gene="EIF5B"
                     /gene_synonym="IF2"
                     /gene_synonym="KIAA0741"
     Protein         1..1220
                     /product="Eukaryotic translation initiation factor 5B"
                     /EC_number="3.6.5.3"
                     /note="eIF-5B; Translation initiation factor IF-2"
                     /UniProtKB_evidence="Evidence at protein level"
     Region          1..1220
                     /region_name="Mature chain"
                     /note="Eukaryotic translation initiation factor 5B.
                     /id=PRO_0000137294."
     Region          1..417
                     /region_name="Region of interest in the sequence"
                     /note="Disordered. /evidence=ECO:0000256|SAM:MobiDB-lite."
     Region          1..21
                     /region_name="Compositionally biased region"
                     /note="Basic and acidic residues.
                     /evidence=ECO:0000256|SAM:MobiDB-lite."
     Region          32..56
                     /region_name="Compositionally biased region"
                     /note="Basic and acidic residues.
                     /evidence=ECO:0000256|SAM:MobiDB-lite."
     Region          64
                     /region_name="Conflict"
                     /note="E -> G (in Ref. 3; BAA34461).
                     /evidence=ECO:0000305."
     Site            66
                     /site_type="phosphorylation"
                     /note="Phosphoserine.
                     /evidence=ECO:0007744|PubMed:23186163."
     Region          78..149
                     /region_name="Compositionally biased region"
                     /note="Basic and acidic residues.
                     /evidence=ECO:0000256|SAM:MobiDB-lite."
     Region          92
                     /region_name="Conflict"
                     /note="T -> I (in Ref. 1; CAB44357).
                     /evidence=ECO:0000305."
     Site            107
                     /site_type="phosphorylation"
                     /note="Phosphoserine.
                     /evidence=ECO:0007744|PubMed:17081983,
                     ECO:0007744|PubMed:18318008, ECO:0007744|PubMed:18669648,
                     ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
                     ECO:0007744|PubMed:24275569."
     Site            113
                     /site_type="phosphorylation"
                     /note="Phosphoserine.
                     /evidence=ECO:0007744|PubMed:17081983,
                     ECO:0007744|PubMed:18318008, ECO:0007744|PubMed:18669648,
                     ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
                     ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
                     ECO:0007744|PubMed:24275569."
     Site            134
                     /site_type="phosphorylation"
                     /note="Phosphotyrosine.
                     /evidence=ECO:0007744|PubMed:18669648,
                     ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:21406692."
     Site            135
                     /site_type="phosphorylation"
                     /note="Phosphoserine.
                     /evidence=ECO:0007744|PubMed:18669648,
                     ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
                     ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
                     ECO:0007744|PubMed:24275569."
     Site            137
                     /site_type="phosphorylation"
                     /note="Phosphoserine.
                     /evidence=ECO:0007744|PubMed:18669648,
                     ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
                     ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
                     ECO:0007744|PubMed:24275569."
     Region          156..199
                     /region_name="Compositionally biased region"
                     /note="Basic and acidic residues.
                     /evidence=ECO:0000256|SAM:MobiDB-lite."
     Site            164
                     /site_type="phosphorylation"
                     /note="Phosphoserine.
                     /evidence=ECO:0007744|PubMed:17081983,
                     ECO:0007744|PubMed:18318008, ECO:0007744|PubMed:18669648,
                     ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
                     ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
                     ECO:0007744|PubMed:24275569."
     Site            171
                     /site_type="phosphorylation"
                     /note="Phosphoserine.
                     /evidence=ECO:0007744|PubMed:21406692."
     Region          180
                     /region_name="Conflict"
                     /note="I -> M (in Ref. 2; AAD16006).
                     /evidence=ECO:0000305."
     Site            182
                     /site_type="phosphorylation"
                     /note="Phosphoserine.
                     /evidence=ECO:0007744|PubMed:18669648,
                     ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
                     ECO:0007744|PubMed:24275569."
     Site            183
                     /site_type="phosphorylation"
                     /note="Phosphoserine.
                     /evidence=ECO:0007744|PubMed:18669648,
                     ECO:0007744|PubMed:19690332."
     Site            186
                     /site_type="phosphorylation"
                     /note="Phosphoserine.
                     /evidence=ECO:0007744|PubMed:18669648,
                     ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
                     ECO:0007744|PubMed:23186163."
     Site            190
                     /site_type="phosphorylation"
                     /note="Phosphoserine. /evidence=ECO:0000269|Ref.5,
                     ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231,
                     ECO:0007744|PubMed:24275569."
     Region          212..284
                     /region_name="Compositionally biased region"
                     /note="Basic and acidic residues.
                     /evidence=ECO:0000256|SAM:MobiDB-lite."
     Site            214
                     /site_type="phosphorylation"
                     /note="Phosphoserine.
                     /evidence=ECO:0007744|PubMed:17081983,
                     ECO:0007744|PubMed:17487921, ECO:0007744|PubMed:17924679,
                     ECO:0007744|PubMed:19367720, ECO:0007744|PubMed:19690332,
                     ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
                     ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569."
     Site            222
                     /site_type="phosphorylation"
                     /note="Phosphoserine.
                     /evidence=ECO:0007744|PubMed:23186163."
     Region          256
                     /region_name="Conflict"
                     /note="K -> R (in Ref. 2; AAD16006).
                     /evidence=ECO:0000305."
     Region          300..339
                     /region_name="Compositionally biased region"
                     /note="Basic and acidic residues.
                     /evidence=ECO:0000256|SAM:MobiDB-lite."
     Site            301
                     /site_type="phosphorylation"
                     /note="Phosphothreonine.
                     /evidence=ECO:0007744|PubMed:18669648,
                     ECO:0007744|PubMed:20068231."
     Region          337
                     /region_name="Variant"
                     /note="S -> G (in dbSNP:rs10642). /id=VAR_055954."
     Region          347..417
                     /region_name="Compositionally biased region"
                     /note="Basic and acidic residues.
                     /evidence=ECO:0000256|SAM:MobiDB-lite."
     Region          360
                     /region_name="Variant"
                     /note="R -> G (in dbSNP:rs3205296). /id=VAR_055955."
     Region          430..608
                     /region_name="Region of interest in the sequence"
                     /note="Disordered. /evidence=ECO:0000256|SAM:MobiDB-lite."
     Region          436..459
                     /region_name="Compositionally biased region"
                     /note="Basic and acidic residues.
                     /evidence=ECO:0000256|SAM:MobiDB-lite."
     Site            438
                     /site_type="phosphorylation"
                     /note="Phosphoserine.
                     /evidence=ECO:0007744|PubMed:23186163."
     Site            478..479
                     /site_type="other"
                     /note="(Microbial infection) Cleavage; by viral protease
                     3C of poliovirus, Coxsackievirus B3 and Human rhinovirus
                     14. /evidence=ECO:0000269|PubMed:18572216."
     Region          488..512
                     /region_name="Compositionally biased region"
                     /note="Acidic residues.
                     /evidence=ECO:0000256|SAM:MobiDB-lite."
     Site            498
                     /site_type="phosphorylation"
                     /note="Phosphothreonine.
                     /evidence=ECO:0007744|PubMed:21406692."
     Region          513..529
                     /region_name="Compositionally biased region"
                     /note="Basic and acidic residues.
                     /evidence=ECO:0000256|SAM:MobiDB-lite."
     Region          522
                     /region_name="Variant"
                     /note="K -> T (in dbSNP:rs7558074).
                     /evidence=ECO:0000269|PubMed:10200264,
                     ECO:0000269|PubMed:10432305, ECO:0007744|PubMed:21269460.
                     /id=VAR_060587."
     Region          530..569
                     /region_name="Compositionally biased region"
                     /note="Acidic residues.
                     /evidence=ECO:0000256|SAM:MobiDB-lite."
     Site            547
                     /site_type="phosphorylation"
                     /note="Phosphoserine.
                     /evidence=ECO:0007744|PubMed:18669648."
     Region          549
                     /region_name="Conflict"
                     /note="E -> V (in Ref. 2; AAD16006).
                     /evidence=ECO:0000305."
     Site            557
                     /site_type="phosphorylation"
                     /note="Phosphoserine.
                     /evidence=ECO:0000250|UniProtKB:B2GUV7."
     Site            560
                     /site_type="phosphorylation"
                     /note="Phosphoserine.
                     /evidence=ECO:0007744|PubMed:18669648."
     Region          570..608
                     /region_name="Compositionally biased region"
                     /note="Basic and acidic residues.
                     /evidence=ECO:0000256|SAM:MobiDB-lite."
     Site            588
                     /site_type="phosphorylation"
                     /note="Phosphoserine.
                     /evidence=ECO:0007744|PubMed:18669648,
                     ECO:0007744|PubMed:20068231."
     Site            589
                     /site_type="phosphorylation"
                     /note="Phosphoserine.
                     /evidence=ECO:0007744|PubMed:20068231."
     Site            591
                     /site_type="phosphorylation"
                     /note="Phosphoserine.
                     /evidence=ECO:0007744|PubMed:20068231."
     Site            595
                     /site_type="phosphorylation"
                     /note="Phosphoserine.
                     /evidence=ECO:0007744|PubMed:18669648,
                     ECO:0007744|PubMed:20068231."
     Region          603..622
                     /region_name="Helical region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          627..1202
                     /region_name="PRK04004"
                     /note="translation initiation factor IF-2; Validated;
                     cl44330"
                     /db_xref="CDD:457675"
     Region          629..846
                     /region_name="Domain"
                     /note="tr-type G.
                     /evidence=ECO:0000255|PROSITE-ProRule:PRU01059."
     Region          633..637
                     /region_name="Beta-strand region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          638..645
                     /region_name="Region of interest in the sequence"
                     /note="G1.
                     /evidence=ECO:0000255|PROSITE-ProRule:PRU01059."
     Region          639..646
                     /region_name="Beta-strand region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Site            640
                     /site_type="mutagenized"
                     /note="V->G: Loss of activity in vivo. Retains full
                     activity in vitro. /evidence=ECO:0000269|PubMed:10200264."
     Region          647..652
                     /region_name="Helical region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          661..664
                     /region_name="Beta-strand region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          663..667
                     /region_name="Region of interest in the sequence"
                     /note="G2.
                     /evidence=ECO:0000255|PROSITE-ProRule:PRU01059."
     Region          669
                     /region_name="Conflict"
                     /note="G -> W (in Ref. 2; AAD16006).
                     /evidence=ECO:0000305."
     Region          676..685
                     /region_name="Helical region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          699..702
                     /region_name="Beta-strand region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          702..705
                     /region_name="Region of interest in the sequence"
                     /note="G3.
                     /evidence=ECO:0000255|PROSITE-ProRule:PRU01059."
     Site            706
                     /site_type="active"
                     /note="/evidence=ECO:0000305|PubMed:35732735."
     Site            706
                     /site_type="mutagenized"
                     /note="H->E: Loss of activity; both in vivo and in vitro.
                     Loss of EIF5B release from the 80S initiation complex,
                     certainly due to loss of ability to hydrolyze GTP.
                     /evidence=ECO:0000269|PubMed:10200264,
                     ECO:0000269|PubMed:35732735."
     Site            706
                     /site_type="mutagenized"
                     /note="H->Q: Loss of activity in vivo. Partial activity in
                     vitro. /evidence=ECO:0000269|PubMed:10200264."
     Region          708..711
                     /region_name="Helical region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          721..726
                     /region_name="Beta-strand region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          729..731
                     /region_name="Helical region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          735..746
                     /region_name="Helical region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          751..755
                     /region_name="Beta-strand region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          756..759
                     /region_name="Region of interest in the sequence"
                     /note="G4.
                     /evidence=ECO:0000255|PROSITE-ProRule:PRU01059."
     Region          757..759
                     /region_name="Beta-strand region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Site            759
                     /site_type="mutagenized"
                     /note="D->N: Loss of activity; both in vivo and in vitro.
                     /evidence=ECO:0000269|PubMed:10200264."
     Region          772..777
                     /region_name="Helical region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          781..799
                     /region_name="Helical region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          800..802
                     /region_name="Hydrogen bonded turn"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          808..811
                     /region_name="Beta-strand region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          814..816
                     /region_name="Hydrogen bonded turn"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          818..822
                     /region_name="Beta-strand region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          824..827
                     /region_name="Beta-strand region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          824..826
                     /region_name="Region of interest in the sequence"
                     /note="G5.
                     /evidence=ECO:0000255|PROSITE-ProRule:PRU01059."
     Region          831..844
                     /region_name="Helical region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          857..866
                     /region_name="Beta-strand region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          867..869
                     /region_name="Hydrogen bonded turn"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          870..879
                     /region_name="Beta-strand region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          887..890
                     /region_name="Beta-strand region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          894
                     /region_name="Conflict"
                     /note="E -> K (in Ref. 1; CAB44357).
                     /evidence=ECO:0000305."
     Region          897..900
                     /region_name="Beta-strand region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          903..906
                     /region_name="Beta-strand region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          913..915
                     /region_name="Beta-strand region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          920..923
                     /region_name="Beta-strand region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          927..934
                     /region_name="Beta-strand region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          943..949
                     /region_name="Beta-strand region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          952..954
                     /region_name="Beta-strand region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          961..963
                     /region_name="Hydrogen bonded turn"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          981..987
                     /region_name="Beta-strand region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          988..1001
                     /region_name="Helical region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          1005..1013
                     /region_name="Beta-strand region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          1015..1025
                     /region_name="Helical region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          1029..1031
                     /region_name="Hydrogen bonded turn"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          1033..1038
                     /region_name="Beta-strand region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          1043..1051
                     /region_name="Helical region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          1055..1061
                     /region_name="Beta-strand region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          1062..1081
                     /region_name="Helical region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          1086..1088
                     /region_name="Beta-strand region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          1092..1096
                     /region_name="Beta-strand region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          1105..1117
                     /region_name="Beta-strand region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Site            1105
                     /site_type="mutagenized"
                     /note="R->A: Disruption of contacts with the Met-tRNA
                     acceptor stem; when associated with A-1174.
                     /evidence=ECO:0000269|PubMed:35732735."
     Region          1125..1135
                     /region_name="Beta-strand region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          1138..1143
                     /region_name="Beta-strand region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          1157..1161
                     /region_name="Beta-strand region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Site            1168
                     /site_type="phosphorylation"
                     /note="Phosphoserine.
                     /evidence=ECO:0007744|PubMed:23186163."
     Region          1173..1175
                     /region_name="Hydrogen bonded turn"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Site            1174
                     /site_type="mutagenized"
                     /note="R->A: Disruption of contacts with the Met-tRNA
                     acceptor stem; when associated with A-1105.
                     /evidence=ECO:0000269|PubMed:35732735."
     Region          1182..1184
                     /region_name="Beta-strand region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          1188..1195
                     /region_name="Helical region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Site            1188..1189
                     /site_type="mutagenized"
                     /note="RQ->ER: Disruption of contacts with eIF1A (EIF1AX);
                     when associated with E-1199 and 1218-R-R-1219.
                     /evidence=ECO:0000269|PubMed:35732735."
     Region          1199..1202
                     /region_name="Beta-strand region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Site            1199
                     /site_type="mutagenized"
                     /note="R->E: Disruption of contacts with eIF1A (EIF1AX);
                     when associated with 1188-E-E-1189 and 1218-R-R-1219.
                     /evidence=ECO:0000269|PubMed:35732735."
     Region          1209..1214
                     /region_name="Helical region"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Region          1215..1218
                     /region_name="Hydrogen bonded turn"
                     /note="/evidence=ECO:0007829|PDB:7TQL."
     Site            1218..1219
                     /site_type="mutagenized"
                     /note="EI->RR: Disruption of contacts with eIF1A (EIF1AX);
                     when associated with 1188-E-R-1189 and E-1199.
                     /evidence=ECO:0000269|PubMed:35732735."
ORIGIN      
        1 mgkkqknkse dstkddidld alaaeiegag aakeqepqks kgkkkkekkk qdfdeddilk
       61 eleelsleaq gikadretva vkptenneee ftskdkkkkg qkgkkqsfdd ndseeledkd
      121 skskktakpk vemysgsddd ddfnklpkka kgkaqksnkk wdgseededn skkikersri
      181 nssgesgdes deflqsrkgq kknqknkpgp niesgneddd asfkiktvaq kkaekkerer
      241 kkrdeekakl rklkekeele tgkkdqskqk esqrkfeeet vkskvtvdtg vipaseekae
      301 tptaaeddne gdkkkkdkkk kkgekeekek ekkkgpskat vkamqealak lkeeeerqkr
      361 eeeerikrle eleakrkeee rleqekrerk kqkekerker lkkegklltk sqreararae
      421 atlkllqaqg vevpskdslp kkrpiyedkk rkkipqqles kevsesmelc aavevmeqgv
      481 pekeetpppv epeeeedted aglddweama sdeetekveg nkvhievken peeeeeeeee
      541 eeedeeseee eeeegesegs egdeedekvs dekdsgktld kkpskemssd seydsdddrt
      601 keeraydkak rriekrrleh sknvnteklr apiicvlghv dtgktkildk lrhthvqdge
      661 aggitqqiga tnvpleaine qtkmiknfdr envripgmli idtpghesfs nlrnrgsslc
      721 diailvvdim hglepqties inllkskkcp fivalnkidr lydwkkspds dvaatlkkqk
      781 kntkdefeer akaiivefaq qglnaalfye nkdprtfvsl vptsahtgdg mgsliyllve
      841 ltqtmlskrl ahceelraqv mevkalpgmg ttidviling rlkegdtiiv pgvegpivtq
      901 irglllpppm kelrvknqye khkeveaaqg vkilgkdlek tlaglpllva ykedeipvlk
      961 delihelkqt lnaikleekg vyvqastlgs lealleflkt sevpyagini gpvhkkdvmk
     1021 asvmlehdpq yavilafdvr ierdaqemad slgvrifsae iiyhlfdaft kyrqdykkqk
     1081 qeefkhiavf pckikilpqy ifnsrdpivm gvtveagqvk qgtpmcvpsk nfvdigivts
     1141 ieinhkqvdv akkgqevcvk iepipgespk mfgrhfeatd ilvskisrqs idalkdwfrd
     1201 emqksdwqli velkkvfeii
//

